You are here

Brent Saunders

Bausch + Lomb's Saunders doesn't expect more big deals in the near term

Bausch + Lomb's Saunders doesn't expect more big deals in the near term

Reuters

Flag link:

Brent Saunders to Return as Bausch + Lomb CEO

Brent Saunders to Return as Bausch + Lomb CEO

US News Money

Flag link:

Low-profile eye drop developer spells out the game plan that drew Brent Saunders to the board — and it involves going earlier than anti-VEGFs

Low-profile eye drop developer spells out the game plan that drew Brent Saunders to the board — and it involves going earlier than anti-VEGFs

Endpoints

diabetic retinopathy

wet age-related macular degeneration

Flag link:

Vesper Healthcare Acquisition, a SPAC led by the former CEO of Allergan, files for a $400 million IPO

Vesper Healthcare Acquisition, a SPAC led by the former CEO of Allergan, files for a $400 million IPO

NASDAQ

Vesper Healthcare Acquisition

Flag link:

Allergan ex-CEO Saunders takes board seat at BridgeBio

Allergan ex-CEO Saunders takes board seat at BridgeBio

Fierce Biotech

Flag link:

Allergan CEO Saunders lines up for $39M parachute after AbbVie buy

Allergan CEO Saunders lines up for $39M parachute after AbbVie buy

Fierce Pharma

Flag link:

How Brent Saunders’ Allergan experiment failed

How Brent Saunders’ Allergan experiment failed

Stat

Flag link:

Allergan chief Saunders takes a painful $2.5B hit on an ugly PhIII flop

Allergan chief Saunders takes a painful $2.5B hit on an ugly PhIII flop

Endpoints

Flag link:

Allergan CEO Saunders hangs on to chairman's title, winning shareholder support — but not by a big enough margin to squelch critics

Allergan CEO Saunders hangs on to chairman's title, winning shareholder support — but not by a big enough margin to squelch critics

Endpoints

Flag link:

‘Something needs to change’: An Allergan analyst spells out why next week’s vote could still spark a major revamp

‘Something needs to change’: An Allergan analyst spells out why next week’s vote could still spark a major revamp

Endpoints

Flag link:

Influential proxy firms kick back at activists’ demands for Brent Saunders to give up his chairman’s title at Allergan

Influential proxy firms kick back at activists’ demands for Brent Saunders to give up his chairman’s title at Allergan

Endpoints

Flag link:

What do Allergan activists really want? A new CEO to replace Saunders, analyst says

What do Allergan activists really want? A new CEO to replace Saunders, analyst says

Fierce Pharma

Flag link:

Sorry, Allergan. Another activist backs an immediate split to CEO, chairman jobs

Sorry, Allergan. Another activist backs an immediate split to CEO, chairman jobs

Fierce Pharma

Flag link:

Under-pressure Allergan backs a CEO-chairman job split—just not right now

Under-pressure Allergan backs a CEO-chairman job split—just not right now

Fierce Pharma

Flag link:

What's next for embattled Allergan? Depends on pipeline performance, analysts say

What's next for embattled Allergan? Depends on pipeline performance, analysts say

Fierce Pharma

Flag link:

Old CEO, new chairman? Some Allergan investors want Pyott to come back: report

Old CEO, new chairman? Some Allergan investors want Pyott to come back: report

Fierce Pharma

Flag link:

Saunders: All options remain on the table for Allergan

Saunders: All options remain on the table for Allergan

Biopharma Dive

Flag link:

Forget that 'no breakup' vow. Allergan's CEO now says a strategic review is happening

Forget that 'no breakup' vow. Allergan's CEO now says a strategic review is happening

Fierce Pharma

Flag link:

Lousy year for shareholders, but Allergan CEO Brent Saunders sprints past Gorsky, Gonzalez with $32M pay package

Lousy year for shareholders, but Allergan CEO Brent Saunders sprints past Gorsky, Gonzalez with $32M pay package

Endpoints

Richard Gonzalez

Flag link:

Don't expect Restasis generics till at least next quarter, Allergan CEO says

Don't expect Restasis generics till at least next quarter, Allergan CEO says

Fierce Pharma

Flag link:

Pages